From June 20 to 23, 2025, Gan & Lee Pharmaceuticals will be at the American Diabetes Association^®’s 85th Scientific Sessions, the world’s largest diabetes meeting, where leading physicians, scientists, researchers, and health care professionals come to learn about the latest findings in diabetes research, prevention, and care.  This year’s event will be held at the McCormick Place Convention Center in Chicago, USA.

Gan & Lee Pharmaceutical Booth Information

Date & Times: June 20-23, 2025 
June 20, 2025: 6:30 PM-8:30 PM CT
June 21-22, 2025: 10:00 AM-4:00 PM CT
June 23, 2025: 10:00 AM-2:00 PM CT
Location: McCormick Place Convention Center, Chicago, IL
Booth Number: #2614

Gan & Lee Pharmaceuticals, a leading pharmaceutical innovator in China, will present four groundbreaking research findings at the Scientific Sessions via oral presentations and featured posters. These studies focus on two cutting-edge therapeutic areas: ultra-long-acting GLP-1 receptor agonists (GLP-1 RAs) and weekly basal insulin formulations, revealing pivotal clinical data. The study abstracts have been accepted for publication in Diabetes^®, the official journal of ADA, with the following presentations:

Biweekly GLP-1RA GZR18 Injection: Phase II Clinical Data Debut

Study 1: A Multicenter, Randomized, Controlled, Phase IIa, Clinical Trial to Evaluate the Efficacy and Safety of GZR-18 Injection in Chinese Patients With Type 2 Diabetes Mellitus (Poster No. 769-P)

Study 2: Phase II head-to-head trial comparing GZR18 with Semaglutide (Ozempic^®) in Chinese T2DM patients (Poster No. 752-P)

Weekly Basal Insulin GZR4 Injection: Phase II Clinical Data Premiere

Study A: A Phase II, Clinical Trial Comparing the Efficacy and Safety of Once-weekly GZR4 Injection Versus Once-daily insulin degludec in Subjects With T2DM on OAD Therapy (Study Part A) or OAD Therapy in Combination With Basal Insulin (Study Part B) (Poster No. 807-P and No. 808-P)

The presentation of the research findings will take place in the Poster Hall of McCormick Place Convention Center from 12:30-1:30 PM local time on June 22.

At Gan & Lee Pharmaceuticals, we uphold "Scientific Excellence" as our core value, driving breakthroughs in diabetes therapeutics through global collaboration and continuous innovation. As China's leading innovator in the field, we are committed to developing safer, more effective treatment solutions to improve patient outcomes worldwide.

We cordially invite the global medical community to explore these cutting-edge findings at the American Diabetes Association’s 85th Scientific Sessions and stay updated through Gan & Lee Pharmaceuticals' official communication channels for subsequent research developments.

About Bofanglutide (GZR18)

Bofanglutide (R&D Code: GZR18) injection, developed by Gan & Lee Pharmaceuticals, is a bi-weekly GLP-1 receptor agonist (RA) indicated for glycemic control in adults with type 2 diabetes and body weight management in overweight/obese individuals. As the potential first bi-weekly GLP-1 RA in the world, early clinical trials have demonstrated its efficacy in weight reduction comparable to or superior to marketed counterparts, with a safety and tolerability profile consistent with the established class of GLP-1 RAs, and significant reductions in both blood glucose levels and body weight.

About GZR4

Gan & Lee Pharmaceuticals' independently developed GZR4  injection is an ultra-long-acting weekly insulin preparation that is expected to provide more stable glucose-lowering effects and reduced intra- or inter-day blood glucose variability. GZR4 is anticipated to help patients with diabetes overcome injection barriers, enable earlier initiation of insulin therapy, optimize long-term diabetes management, and enhance patients' quality of life via once-weekly subcutaneous injection. Early clinical findings indicate that GZR4 demonstrates comparable reduction in HbA1c to insulin degludec in patients with inadequate glycemic control through oral antidiabetic medications. Currently, the global development of GZR4 has entered the Phase 3 clinical trial stage.

Forward-looking statements

Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.